Cancer drugs to lose crown

 Posted 26 March 2024 AM

Blockbuster cancer treatments - including MSD's Keytruda and BMS' Opdivo - are set to be dethroned as the top-selling drug class in the world before the end of the year, according to a new analysis.

A report by GlobalData predicts "the status quo is poised for a shift" with the PD1 antagonist medicine class to be toppled by the GLP1 agonists, used in obesity and diabetes and which include Novo Nordisk's Wegovy and Eli Lilly's Mounjaro.

To see the whole article, please login